Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators
2019-02-20
FDA-2014-D-1939
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Use of Investigational Tobacco Products Draft Guidance for Industry and Investigators February 2019
Not for implementation. Contains non-binding recommendations.
Section 910(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 16 387j(g)) gives FDA the authority to issue regulations to exempt tobacco products intended for investigational use from the requirements of chapter IX of the FD&C Act, including premarket submission requirements. To date, FDA has not issued such regulations; consequently, investigational tobacco products are not exempt from FD&C Act requirements, including premarket submission requirements. This draft guidance supersedes the draft guidance of the same title dated September 2015 and, when final, will describe FDA’s current thinking regarding the definition of investigational tobacco product and discuss the kind of information FDA intends to consider in making enforcement decisions regarding the use of investigational tobacco products until regulations are issued and become effective or FDA provides written notice of its intent to change its enforcement policy.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
Investigators who are designing a protocol involving administration of a tobacco product to humans should review the information below regarding the need for submitting their protocol to Food and Drug Administration (FDA) Center for Tobacco Products (CTP) for review.
Investigators are encouraged to work with tobacco product manufacturers to ensure availability of products to complete planned studies. FDA evaluates the specific uses of investigational tobacco products (ITPs) on a case-by-case basis according to potential human subject protection concerns or other impacts on public health. Generally, submission of protocols by industry and academic researchers for FDA review is a voluntary process; however, FDA will review all protocols submitted. FDA recommends submission of proposed use of ITPs to FDA for review only if the study design is more likely to raise concerns about human subject protection, public health, or both. As discussed by FDA in its February 2019 guidance, Use of Investigational Tobacco Products, factors to consider would be studies that plan to enroll vulnerable populations, particularly those < 21 years old, studies that involve significant increases over the participants’ usual exposure to nicotine, studies that modify the tobacco product in a manner different from that described by the manufacturer or study of a novel product for which there is limited experience and knowledge.
For all clinical studies involving use of ITPs, we recommend that you notify FDA, all participating clinical investigators, and any committee or group formally designated to oversee the study of any serious or unexpected adverse experience associated with the tobacco product you are investigating within a few weeks after initial notification, and that you supply FDA with a completed case report form for the adverse experience. We encourage the reporting of adverse experiences associated with a clinical investigation of an investigational tobacco product to FDA through the FDACTP Safety Reporting Portal for Researchers.
FDA is committed to furthering scientific research on tobacco products and has a major investment in regulatory science. If you plan to study tobacco products that do not have marketing authorization or that do not comply with an applicable tobacco product standard, you may submit your proposed protocol to FDA for review based on the criteria described above. FDA will review any protocols submitted and intends to evaluate specific uses of investigational tobacco products on a case-by-case basis according to potential human subject protection concerns or other impacts on public health. Generally, FDA does not recommend that investigators correspond with us about the use of investigational tobacco products in nonclinical studies as these are not ordinarily reviewed. You may refer to the draft guidance, Use of Investigational Tobacco Products, for more information regarding how to submit your proposed use of an investigational tobacco product and how FDA intends to make enforcement decisions regarding the use of investigational tobacco products.
FDA understands that investigators may choose to obtain tobacco products directly from a tobacco product manufacturer with the sole intent to use the products for research investigations without commercializing the products. In such cases, FDA recommends that investigators add language to all product labels to indicate that these products are limited to investigational use, that study participants be instructed that the products may not be further distributed, and that study protocols include a plan to collect and account for all investigational tobacco products after the study has concluded.
If there are additional questions, investigators should reach out to the FDA CTP at: CTP-OS-ITP@fda.hhs.gov.
The email should:
- Clearly and uniquely identify the product(s) you wish to study by brand and sub-brand—including the type or category of tobacco product (e.g., cigarette, smokeless tobacco, cigar, electronic nicotine delivery systems [ENDS], waterpipe tobacco) and subcategory (e.g., closed or open e-cigarette, closed or open e-liquid).
- Provide additional available information such as packaging type, package quantity, and/or characterizing flavor that may help answer the specific question(s)
Once the FDA CTP receives the email, they will make every effort to respond via email within 2weeks.
Note that the FDA CTP intends to respond to investigators within 60 days of receipt of protocols for review. Investigators should receive acknowledgement of the submission with the name and contact information for the assigned Regulatory Health Project Manager (RHPM). If investigators do not receive a response within 60 days, they should contact the RHPM. Investigators may also contact their NIH Program Officer to discuss additional steps/actions.
If the marketed products will be used with investigator-manipulated modification(s), then the investigator should submit an ITP request. In addition to the protocol and other information described in the FDA Draft Guidance, the ITP request should also include:
- A description of the planned modification(s).
- A rationale for how these modification(s) support the study design and do not increase risk to human participants.
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2014-D-1939.
Questions?
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-14
-
2026-10-14
-
摩熵咨询 35 78
-
摩熵咨询 28 65
-
颁布机构:国家市场监督管理总局 2026-09-30
-
颁布机构:国家市场监督管理总局 2026-09-29
最新指导原则
-
国家药监局器审中心关于发布<人表皮生长因子受体2基因扩增检测试剂(荧光原位杂交法)注册审查指导原则(2026年修订版)>等2项注册审查指导原则的通告(2026年第28号)
2026-10-13
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
国家药监局器审中心关于发布有源植入式医疗器械电池注册审查指导原则的通告(2026年第27号)
2026-10-08
-
国家药监局器审中心关于发布腹腔内窥镜手术系统注册审查指导原则 第5部分:患者模型试验研究>的通告(2026年第26号)
2026-09-28
-
国家药监局综合司公开征求<医疗器械生产质量管理规范无菌医疗器械检查指导原则(征求意见稿)>等意见
2026-09-24
-
关于公开征求ich<e14/s7b:问答:致qt/qtc 间期延长及潜在致心律失常作用的临床和非临床评价问答>指导原则问答文件实施建议和中文翻译稿意见的通知
2026-09-24
-
国家药监局药审中心关于发布<药物临床试验计算机化系统和电子数据指导原则>的通告
2026-09-22
-
国家药监局药审中心关于发布<化学仿制药滴眼剂研究技术指导原则>和<化学仿制药特殊滴眼剂研究技术指导原则>的通告
2026-09-02
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
国家卫生健康委办公厅关于印发医疗机构卒中中心建设与管理指导原则(2026年版)的通知
2026-07-28
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-15
-
2026-10-15
-
2026-10-15
-
摩熵咨询 33 34
-
摩熵咨询 20 8
-
摩熵咨询 20 12
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
同部门最新指导原则
-
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
2024-11-15
-
Guidance for Industry: FDA's Voluntary Qualified Importer Program
2024-11-14
-
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24)
2024-11-01
-
Study Data Technical Conformance Guide - Technical Specifications Document
2024-10-31
-
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
2024-10-30
-
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients
2024-10-24
-
Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination
2024-10-22
-
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling
2024-10-21
-
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA
2024-10-17
-
Postoperative Nausea and Vomiting: Developing Drugs for Prevention
2024-10-17
-
Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method
2024-10-17
-
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry
2024-10-17
-
Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry
2024-10-17
-
Requests for Reconsideration at the Division Level Under GDUFA
2024-10-16
-
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food
2024-10-15
同地域最新指导原则
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
-
opioid analgesic drugs: considerations for benefit-risk assessment framework(阿片类镇痛药:效益-风险评估框架的考量)
2026-05-13
-
development of non-opioid analgesics for acute pain(急性疼痛的非阿片类镇痛药开发)
2026-05-13
-
development of local anesthetic drug products with prolonged duration of effect(延长作用时间的局部麻醉药品的开发)
2026-05-13
-
stimulant use disorders: developing drugs for treatment(兴奋剂使用障碍:治疗药物的开发)
2026-05-13
-
development of non-opioid analgesics for chronic pain(慢性疼痛非阿片类镇痛药的开发)
2026-05-13
-
pulmonary tuberculosis: developing drugs for treatment(肺结核:治疗药物的开发)
2026-05-08
-
clostridioides difficile infection: developing drugs for treatment, reduction of recurrence, and prevention(艰难梭菌感染:用于治疗、减少复发及预防的药物开发)
2026-05-08
-
enforcement priorities for certain new tobacco products marketed without premarket authorization(未经上市前授权销售的某些新烟草产品的执法重点)
2026-05-08

